ScholarLens Back to search
2020•StrokeOpen access

Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice

Frieder Schlunk, Paul Fischer, P. Hans, André Rex, Vincent Prinz, Marco Foddis, Dieter Lütjohann, Ulrich Laufs, Matthias Endres

Open full text 4 citations

Abstract

Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of intracerebral hemorrhage (ICH),2 and hematoma growth was increased with low serum cholesterol.3,4 The objective of this study was to test the effects of PCSK9 inhibition or genetic deletion on hematoma volume after experimental ICH collagenase model) using 3 different strain of mice (ie, hypercholesterolemic, normocholesterolemic, PCSK9−/− versus controls).

Open-access reader

About this research paper

What this paper is about

Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of intracerebral hemorrhage (ICH),2 and hematoma growth was increased with low serum cholesterol.3,4 The objective of this study was to test the effects of PCSK9 inhibition or genetic deletion on hematoma volume after experimental ICH collagenase model) using 3 different strain of mice (ie, hypercholesterolemic, normocholesterolemic, PCSK9−/− versus controls).

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of intracerebral hemorrhage (ICH),2 and hematoma growth was increased with low serum cholesterol.3,4 The objective of this study was to test the effects of PCSK9 inhibition or genetic deletion on hematoma volume after experimental ICH collagenase model) using 3 different strain of mice (ie, hypercholesterolemic, normocholesterolemic, PCSK9−/− versus controls).

Key concepts: Kexin, PCSK9, Medicine, Intracerebral hemorrhage, Neurology, Proprotein convertase, Subtilisin, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Effects of Inhibition or Deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on Intracerebral Hemorrhage Volumes in Mice — Research Paper | ScholarLens